ImmuCell Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . ImmuCell
ICCC Stock  USD 5.92  0.23  3.74%   
ImmuCell's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ImmuCell's valuation are provided below:
Gross Profit
11 M
Profit Margin
0.0623
Market Capitalization
54.7 M
Enterprise Value Revenue
2.3534
Revenue
28.3 M
We have found one hundred twenty available fundamental trends for ImmuCell, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to confirm all of ImmuCell's regular performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 37 M. The current year's Enterprise Value is expected to grow to about 51.9 M

ImmuCell Total Revenue

31.99 Million

Check ImmuCell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmuCell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 686.7 K or Total Revenue of 32 M, as well as many indicators such as Price To Sales Ratio of 1.69, Dividend Yield of 0.0 or PTB Ratio of 1.8. ImmuCell financial statements analysis is a perfect complement when working with ImmuCell Valuation or Volatility modules.
  
Build AI portfolio with ImmuCell Stock
Check out the analysis of ImmuCell Correlation against competitors.
For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

ImmuCell Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets54.5 M51.9 M30.5 M
Slightly volatile
Short and Long Term Debt Total18.2 M17.4 M8.2 M
Slightly volatile
Other Current Liabilities1.9 M1.8 M795.2 K
Slightly volatile
Total Current Liabilities5.3 M5.1 M2.4 M
Slightly volatile
Total Stockholder Equity33.2 M31.6 M20.8 M
Slightly volatile
Property Plant And Equipment Net36.1 M34.4 M19 M
Slightly volatile
Cash2.6 M4.3 M3.7 M
Slightly volatile
Non Current Assets Total36.3 M34.6 M19.6 M
Slightly volatile
Non Currrent Assets Other28.5 K30 K38.7 K
Pretty Stable
Cash And Short Term Investments4.2 M4.3 M5.2 M
Very volatile
Net Receivables4.6 M4.4 M1.8 M
Slightly volatile
Common Stock Shares Outstanding9.9 M9.4 M5.7 M
Slightly volatile
Liabilities And Stockholders Equity54.5 M51.9 M30.5 M
Slightly volatile
Non Current Liabilities Total15.2 M15.1 M7.3 M
Slightly volatile
Inventory8.6 M8.2 M3.4 M
Slightly volatile
Other Current Assets248.8 K324.2 K385.2 K
Slightly volatile
Other Stockholder Equity49.2 M46.9 M24.9 M
Slightly volatile
Total Liabilities21.2 M20.2 M9.7 M
Slightly volatile
Total Current Assets18.2 M17.3 M10.9 M
Slightly volatile
Short Term Debt1.6 M1.7 M837.8 K
Slightly volatile
Accounts Payable1.1 M1.1 M681.5 K
Slightly volatile
Property Plant And Equipment Gross61.5 M58.6 M26 M
Slightly volatile
Common Stock Total Equity426.5 K839.4 K541 K
Slightly volatile
Common Stock1.1 M1 M611.2 K
Slightly volatile
Other Assets0.860.9462 K
Slightly volatile
Long Term Debt5.3 M10.4 M5.7 M
Slightly volatile
Property Plant Equipment37 B35.2 B9.7 B
Slightly volatile
Other Liabilities85590027.3 K
Slightly volatile
Current Deferred Revenue248.4 K261.5 K163.4 K
Slightly volatile
Net Tangible Assets36.5 B34.8 B9.5 B
Slightly volatile
Long Term Debt Total10.6 M10 M5.9 M
Slightly volatile
Capital Surpluse19.4 M36.1 M21.6 M
Slightly volatile
Deferred Long Term Asset Charges695.2 K425.5 K695.2 K
Slightly volatile
Short and Long Term Debt888.9 K1.7 M711.8 K
Slightly volatile
Net Invested Capital40.8 M43.8 M35.8 M
Slightly volatile
Net Working Capital10 M12.2 M7.8 M
Slightly volatile
Capital Stock828.9 K1 M686.7 K
Slightly volatile
Non Current Liabilities Other908.1 K1 M1.1 M
Slightly volatile

ImmuCell Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.2 M3.1 M1.6 M
Slightly volatile
Total Revenue32 M30.5 M14.2 M
Slightly volatile
Gross Profit9.6 M9.1 M5.7 M
Slightly volatile
Other Operating Expenses34 M32.4 M15.2 M
Slightly volatile
Cost Of Revenue22.4 M21.3 M8.5 M
Slightly volatile
Total Operating Expenses11.6 M11 M6.7 M
Slightly volatile
Research Development4.7 M4.5 M2.9 M
Slightly volatile
Selling General Administrative1.5 M2.5 M1.6 M
Slightly volatile
Selling And Marketing Expenses2.3 M4 M2.5 M
Slightly volatile
Interest Income75.5 K89.4 K68 K
Slightly volatile
Reconciled Depreciation2.4 M3.1 M1.7 M
Slightly volatile
Extraordinary Items56.8 K63.9 K69.7 K
Slightly volatile

ImmuCell Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.1 M1.1 M3.2 M
Slightly volatile
Depreciation3.2 M3.1 M1.6 M
Slightly volatile
End Period Cash Flow2.6 M4.3 M3.6 M
Slightly volatile
Stock Based Compensation393.6 K374.9 K189 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.691.432.5917
Slightly volatile
PTB Ratio1.81.761.7258
Slightly volatile
Days Sales Outstanding32.4247.2642.2424
Slightly volatile
Book Value Per Share2.13.033.4683
Pretty Stable
Average Payables367.7 K690.8 K773.5 K
Slightly volatile
Stock Based Compensation To Revenue0.01020.01110.0124
Slightly volatile
Capex To Depreciation0.150.162.5521
Pretty Stable
PB Ratio1.81.761.7258
Slightly volatile
EV To Sales1.621.812.7533
Pretty Stable
Inventory Turnover3.233.02.6719
Pretty Stable
Days Of Inventory On Hand115126153
Slightly volatile
Payables Turnover11.4217.6912.9649
Slightly volatile
Sales General And Administrative To Revenue0.09140.09620.1386
Slightly volatile
Average Inventory4.3 M4.1 M2.8 M
Slightly volatile
Research And Ddevelopement To Revenue0.280.170.2313
Pretty Stable
Capex To Revenue0.0150.01580.2276
Very volatile
Cash Per Share0.390.411.0603
Slightly volatile
Days Payables Outstanding38.8621.3538.1486
Slightly volatile
Intangibles To Total Assets0.00280.00290.0078
Slightly volatile
Current Ratio3.723.926.1561
Slightly volatile
Tangible Book Value Per Share2.063.023.4456
Pretty Stable
Receivables Turnover10.437.998.971
Slightly volatile
Shareholders Equity Per Share2.13.033.4683
Pretty Stable
Debt To Equity0.520.490.3205
Slightly volatile
Capex Per Share0.04880.05130.5118
Very volatile
Average Receivables2.8 M2.7 M1.6 M
Slightly volatile
Revenue Per Share1.552.922.2464
Slightly volatile
Interest Debt Per Share1.811.731.2222
Slightly volatile
Debt To Assets0.320.30.2166
Slightly volatile
Graham Number2.663.23.2345
Slightly volatile
Operating Cycle146173192
Pretty Stable
Price Book Value Ratio1.81.761.7258
Slightly volatile
Days Of Payables Outstanding38.8621.3538.1486
Slightly volatile
Company Equity Multiplier1.061.481.3575
Slightly volatile
Long Term Debt To Capitalization0.130.220.1816
Slightly volatile
Total Debt To Capitalization0.330.320.2274
Slightly volatile
Debt Equity Ratio0.520.490.3205
Slightly volatile
Quick Ratio1.541.624.6485
Slightly volatile
Net Income Per E B T0.961.160.8201
Slightly volatile
Cash Ratio0.930.982.007
Pretty Stable
Cash Conversion Cycle119156159
Very volatile
Days Of Inventory Outstanding115126153
Slightly volatile
Days Of Sales Outstanding32.4247.2642.2424
Slightly volatile
Price To Book Ratio1.81.761.7258
Slightly volatile
Fixed Asset Turnover0.971.021.9742
Slightly volatile
Debt Ratio0.320.30.2166
Slightly volatile
Price Sales Ratio1.691.432.5917
Slightly volatile
Asset Turnover0.80.680.5096
Very volatile
Gross Profit Margin0.580.340.4765
Slightly volatile
Price Fair Value1.81.761.7258
Slightly volatile

ImmuCell Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap37 M35.3 M30.5 M
Slightly volatile
Enterprise Value51.9 M49.4 M34.7 M
Slightly volatile

ImmuCell Fundamental Market Drivers

ImmuCell Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About ImmuCell Financial Statements

ImmuCell stakeholders use historical fundamental indicators, such as ImmuCell's revenue or net income, to determine how well the company is positioned to perform in the future. Although ImmuCell investors may analyze each financial statement separately, they are all interrelated. For example, changes in ImmuCell's assets and liabilities are reflected in the revenues and expenses on ImmuCell's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ImmuCell. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue261.5 K248.4 K
Total Revenue30.5 M32 M
Cost Of Revenue21.3 M22.4 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.10  0.09 
Research And Ddevelopement To Revenue 0.17  0.28 
Capex To Revenue 0.02  0.02 
Revenue Per Share 2.92  1.55 
Ebit Per Revenue(0.06)(0.06)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc
When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:
How To Invest In ImmuCell
Details
Is ImmuCell Stock a good investment?
Details
What is ImmuCell's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of ImmuCell Correlation against competitors.
For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.63)
Earnings Share
0.21
Revenue Per Share
3.22
Quarterly Revenue Growth
0.178
Return On Assets
0.0302
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY